Shopping Cart

Your shopping cart is currently empty

Ranolazine dihydrochloride

Name: Ranolazine dihydrochloride
Brand: TargetMol
SKU: T0207
Price: 44 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T0207Cas No. 95635-56-6

Alias RS 43285, Ranolazine 2HCl

Ranolazine dihydrochloride (Ranolazine 2HCl) , an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.

Ranolazine dihydrochloride

Copy Product Info

🥰Excellent

Purity: 99.97%

Catalog No. T0207Alias RS 43285, Ranolazine 2HClCas No. 95635-56-6

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$44	In Stock	In Stock
100 mg	$62	In Stock	In Stock
200 mg	$97	In Stock	In Stock
500 mg	$158	In Stock	In Stock
1 g	$217	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$63	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.97%

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Ranolazine dihydrochloride AI Summary

Ranolazine dihydrochloride exhibits broad-spectrum bioactivity against a variety of biological targets and organisms. It demonstrates antiplasmodial activity against Plasmodium falciparum 7G8 with an IC50 value of 5011.87 nM after 72 hours, as assessed using the SYBR green assay. It also shows moderate potency in inhibiting Lamin A splicing (6309.6 nM) and possesses activity against the Neuropeptide S receptor, human PMP22 expression/activity, Bloom's syndrome helicase (BLM), lipid storage modulation, calcium signal transduction, histone lysine methyltransferase G9a, and Marburg Virus entry, with varying potencies ranging from 4466.8 nM to 75686.3 nM. Additionally, Ranolazine dihydrochloride demonstrates antiviral activity by inhibiting SARS-CoV-2 induced cytotoxicity in Caco-2 and VERO-6 cells at 10 µM after 48 hours, and exhibits inhibition percentages of -4.47% and 0.01 MOI respectively. Furthermore, it shows inhibitory activity against SARS-CoV-2 3CL-Pro protease at 20 µM with a -7.584% inhibition. In terms of antifungal and antibacterial properties, it inhibits Candida albicans (1.45%) and Cryptococcus neoformans (-5.35%), as well as Escherichia coli (-4.15%), Klebsiella pneumoniae (1.09%), Pseudomonas aeruginosa (12.05%), Acinetobacter baumannii (15.85%), and Staphylococcus aureus MRSA (15.16%). This extensive range of activities suggests that Ranolazine dihydrochloride has potential therapeutic implications across multiple infectious diseases and biological pathways..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ranolazine dihydrochloride (Ranolazine 2HCl) , an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.
Targets&IC50	IKr:12 μM (IC50), INa:6 μM (IC50)
In vitro	Ranolazine (5 mM and 10 mM) reversibly shortened the duration of twitch contractions and abolished postcontractions.Ranolazine bound more to sodium channels in the inactivated state. In cardiomyocytes, selective inhibition of late I (sodium) by Ranolazine reduced sodium-dependent calcium overload and attenuated ventricular repolarization and contraction, which correlated with abnormalities in heart failure and ischemia/reperfusion injury. In dog left ventricular myocytes, in a concentration-dependent manner Ranolazine was able to reversibly shorten myocyte action potential duration in response to 0.25/0.5 Hz stimulation.
In vivo	Ranolazine (5 mM and 10 mM) reversibly shortened the duration of twitch contractions and abolished postcontractions.Ranolazine bound more to sodium channels in the inactivated state. In cardiomyocytes, selective inhibition of late I (sodium) by Ranolazine reduced sodium-dependent calcium overload and attenuated ventricular repolarization and contraction, which correlated with abnormalities in heart failure and ischemia/reperfusion injury. In dog left ventricular myocytes, in a concentration-dependent manner Ranolazine was able to reversibly shorten myocyte action potential duration in response to 0.25/0.5 Hz stimulation.
Synonyms	RS 43285, Ranolazine 2HCl

Chemical Properties

Molecular Weight	500.46
Formula	C₂₄H₃₅Cl₂N₃O₄
Cas No.	95635-56-6
Smiles	Cl.Cl.COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Relative Density.	no data available

Storage & Solubility Information

Storage

keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 166.7 mg/mL (333.09 mM), Sonication is recommended.

H2O: 250 mg/mL (499.54 mM), Sonication is recommended.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	1.9982 mL	9.9908 mL	19.9816 mL	99.9081 mL
5 mM	0.3996 mL	1.9982 mL	3.9963 mL	19.9816 mL
10 mM	0.1998 mL	0.9991 mL	1.9982 mL	9.9908 mL
20 mM	0.0999 mL	0.4995 mL	0.9991 mL	4.9954 mL
50 mM	0.0400 mL	0.1998 mL	0.3996 mL	1.9982 mL
100 mM	0.0200 mL	0.0999 mL	0.1998 mL	0.9991 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc